No Data
No Data
Dongbao Pharmaceutical Gets Nod to Sell Diabetes Drug in Nicaragua
Tonghua Dongbao Pharmaceutical (600867): Winning bids in centralized procurement support performance growth, with significant results in innovative research and international cooperation.
The company's performance is expected to show a recovery turning point in 2025: According to Tonghua Dongbao Pharmaceutical's 2024 Earnings Reports, the company achieved revenue of 2.01 billion yuan in 2024 (a year-on-year decrease of -34.66%); the net income attributable to shareholders was -0.043 billion yuan (
Express News | Tonghua Dongbao Pharmaceutical: Recombination protein human insulin injection has obtained the pharmaceutical registration certificate in Nicaragua.
Express News | Trump stated that he will sign an executive order on "pharmaceutical price reduction". Tonghua Dongbao Pharmaceutical: this policy will not have an impact in the short term.
Tonghua Dongbao Pharmaceutical (600867): Performance in 2024 is under temporary pressure, but entering with a lighter load is expected to lead to a turning point in performance.
In 2024, the company achieved revenue of 2.01 billion yuan, a decrease of 35% year-on-year; the net income attributable to the shareholders of the listed company was -0.043 billion yuan, a decrease of 104%; the net income attributable to the shareholders of the listed company was
Tonghua Dongbao Pharmaceutical (600867): The annual report & first quarter report meet expectations, with impressive growth in overseas Business.
In 2024 and the first quarter of 2025, the company announced performance in line with our expectations: In 2024, the company revenue was 2.01 billion yuan, a year-on-year decline of 34.66%, net income attributable to the parent company's shareholders.